Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral small molecule therapies for unmet needs.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
RFS
French 927.7 KB
2025-08-25 09:57
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.